Teva Pharmaceutical Industries (TEVA) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. At $33.96, A.R:R 1.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 6.9%; Concentration risk — Product: generic medicines (55.0%).
Teva is a global biopharmaceutical company with ~34,000 employees across 57 markets, operating US, Europe, and International Markets segments. Generic medicines were 55% of 2025 total revenues ($9.4B); key branded products include AUSTEDO (tardive dyskinesia/Huntington's), AJOVY... Read more
Sell if holding. At $33.96, A.R:R 1.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 6.9%; Concentration risk — Product: generic medicines (55.0%). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.8/10, moderate confidence.
Passes 5/7 gates (clean insider activity, no SEC red flags, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-11Recent Developments — Teva Pharmaceutical Industries
Latest news
- NEWS Earnings call transcript: Teva beats Q1 2026 forecasts, stock surges 7.5% - Investing.com — Investing.com positive
- NEWS Teva Pharmaceutical (TEVA) Reports Strong Q1 Earnings, Beats Exp - GuruFocus — GuruFocus positive
- NEWS Teva Surges As Its New Growth Strategy Hits A Key Inflection Point - Investor's Business Daily — Investor's Business Daily positive
- NEWS Teva Surges As New Strategy Hits An Inflection Point - Investor's Business Daily — Investor's Business Daily positive
- NEWS Teva (TEVA) Announces Acquisition of Emalex Biosciences - GuruFocus — GuruFocus positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductgeneric medicines55%10-K Item 1A: 'total revenues from sales of our generic medicines in all our business segments were $9,421 million, or 55% of our total revenues'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $33.96, A.R:R 1.0:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 6.9%; Concentration risk — Product: generic medicines (55.0%). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $31.40. Score 5.8/10, moderate confidence.
Take-profit target: $35.91 (+6.9% upside). Prior stop was $31.40. Stop-loss: $31.40.
Concentration risk — Product: generic medicines (55.0%); Thin upside margin: 6.9%; Leverage penalty (D/E 2.1): -1.5.
Teva Pharmaceutical Industries trades at a P/E of 25.7 (forward 11.1). TrendMatrix value score: 7.2/10. Verdict: Sell.
7 analysts cover TEVA with a consensus score of 4.1/5. Average price target: $41.
What does Teva Pharmaceutical Industries do?Teva is a global biopharmaceutical company with ~34,000 employees across 57 markets, operating US, Europe, and...
Teva is a global biopharmaceutical company with ~34,000 employees across 57 markets, operating US, Europe, and International Markets segments. Generic medicines were 55% of 2025 total revenues ($9.4B); key branded products include AUSTEDO (tardive dyskinesia/Huntington's), AJOVY (migraine), and UZEDY (schizophrenia/BD-1).